Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LB Pharmaceuticals Inc (LBRX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission, alongside AI-assisted summaries to help interpret the information. As a clinical-stage biopharmaceutical company focused on schizophrenia, bipolar depression, and other neuropsychiatric diseases, LB Pharmaceuticals uses SEC filings to report on its financial condition, clinical development plans, corporate governance, and material agreements.
Core documents for LBRX include its registration statement on Form S-1/A, which describes the company’s business, risk factors, and the role of its lead product candidate, LB-102. This filing outlines LB-102’s status as a Phase 3–ready oral, small-molecule drug and a methylated derivative of amisulpride, and explains the company’s focus on neuropsychiatric indications such as acute schizophrenia and bipolar depression. Periodic reports and earnings-related Form 8-K filings provide condensed balance sheets, statements of operations, and narrative updates on research and development and general and administrative expenses.
Other current reports on Form 8-K document material corporate events, including lease amendments for additional office space, appointments of senior executives, and press releases announcing quarterly financial results. These filings also confirm that LB Pharmaceuticals’ common stock is listed on The Nasdaq Stock Market LLC under the ticker LBRX and that the company is incorporated in Delaware.
On Stock Titan, users can review these filings in chronological order and use AI-powered summaries to quickly understand key points from lengthy documents, such as the implications of clinical trial disclosures, changes in operating expenses, or the significance of material agreements. Access to insider transaction reports on Form 4, annual reports on Form 10-K, and quarterly reports on Form 10-Q, when filed, can further support analysis of LBRX’s progress as a clinical-stage biopharmaceutical issuer.
LB Pharmaceuticals Inc. disclosed that BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in the company’s common stock. As of December 31, 2025, BlackRock reported beneficial ownership of 1,277,776 shares, representing 5.1% of LB Pharmaceuticals’ outstanding common stock.
BlackRock reported sole power to vote 1,262,836 shares and sole power to dispose of 1,277,776 shares, with no shared voting or dispositive power. The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals.
BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 961,158 shares, representing 3.8 % of the outstanding common stock. It has sole power to vote 863,342 shares and sole power to dispose of 961,158 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals. Various persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
JPMorgan Chase & Co. has filed a Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 1,611,482 shares, representing 6.3% of the company’s outstanding common stock as of the event date.
JPMorgan has sole voting power over 1,471,295 shares and sole dispositive power over 1,611,482 shares, with no shared voting or dispositive power. The filing is certified as being made in the ordinary course of business and states that the securities are not held for the purpose of changing or influencing control of LB Pharmaceuticals.
LB Pharmaceuticals reported that its chief commercial officer received an employee stock option grant covering 195,000 shares of common stock. The option, dated 12/10/2025, has an exercise price of $21.36 per share and expires on 12/09/2035.
One fourth of the shares vest on 11/10/2026, with the remaining shares vesting in 36 equal monthly installments on the last calendar day of each month starting 12/31/2026, subject to the officer’s continuous service. Following this grant, the officer beneficially owns 195,000 stock options, held directly.
LB Pharmaceuticals Inc. (LBRX) reported that its Chief Commercial Officer, listed as an officer of the company, filed an initial Form 3 statement of beneficial ownership. The filing states that, as of the reported event date, the officer has no securities beneficially owned in LB Pharmaceuticals. This establishes that the executive currently holds no direct or indirect ownership in the company’s securities under the relevant reporting rules.
LB Pharmaceuticals (LBRX) amended its headquarters lease to add 4,634 rentable square feet on the 10th floor at One Penn Plaza, New York. The underlying lease term remains scheduled to expire on March 31, 2032.
The landlord shall endeavor to deliver the Expansion Premises on or prior to July 1, 2026. From the Expansion Premises Commencement Date, fixed rent for the added space will be $430,962 per year for the first three years, increasing to $477,302 per year on the third anniversary. The parties agreed to a fixed rent abatement for the first 150 days after commencement, as set forth in the amendment.
LB Pharmaceuticals (LBRX) appointed Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025, and announced the move via a press release. The company also plans to grant her an equity award as an inducement to join, made outside of—but subject to—the 2025 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). A copy of the press release is filed as Exhibit 99.1.
LB Pharmaceuticals (LBRX) reported Q3 2025 results highlighted by its September IPO and a much stronger balance sheet. The company posted a Q3 net loss of $3.6 million, a significant improvement from $14.2 million a year ago, as research and development ($2.4 million) and general and administrative ($2.8 million) expenses were lower.
The IPO closed on September 12, issuing 21,850,000 shares at $15.00 for $327.8 million gross and $302.3 million net. All preferred shares converted into 3,191,334 common shares immediately prior to closing, following a 1‑for‑27.8874 reverse stock split on September 8. As of September 30, cash and cash equivalents were $269.7 million and marketable securities were $44.7 million, bringing cash and securities to $314.5 million. Management states these resources fund operations for at least twelve months from issuance of the statements.
Total assets were $320.7 million against liabilities of $10.5 million, with stockholders’ equity of $310.2 million. The derivative warrant liability decreased to $0.9 million. 25,299,102 common shares were outstanding as of November 6, 2025. The company’s lead candidate, LB‑102, is described as Phase 3‑ready for acute schizophrenia.
LB Pharmaceuticals (LBRX) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 via an 8-K.
The disclosure under Item 2.02 is expressly stated as “furnished,” not “filed,” which limits its application under Section 18 of the Exchange Act. The filing lists the company’s common stock on The Nasdaq Stock Market under the symbol LBRX, and is signed by Chief Executive Officer Heather Turner.
Marc Panoff, Senior Vice President, Finance of LB Pharmaceuticals, Inc. (LBRX), reported changes to his option holdings on September 10, 2025. The filing shows a one-time option repricing that reduced the exercise price of multiple employee stock options to $15, which the company notes is the issuer's initial public offering price. The report lists several option awards affected: 3,944; 896; 1,255; 14,343; 7,171; and 90,525 shares, with some portions immediately exercisable and others subject to standard vesting schedules. Vesting details are provided for each award and the form is signed by Mr. Panoff on September 12, 2025.